ad

Julio C. Rojas, MD, PhD

Behavioral Neurology Fellow

Julio Rojas received his medical degree from the Tecnológico de Monterrey School of Medicine in Monterrey, Nuevo León, Mexico. He completed his doctoral studies in neuroscience at the University of Texas at Austin with a dissertation on Strategies of neuroprotection in an in vivo model of retinal degeneration induced by mitochondrial dysfunction. He completed neurology residency at UT Southwestern Medical Center in Dallas. In 2014, he joined the UCSF Memory and Aging Center where he is a behavioral neurology fellow. Dr. Rojas is part of the Clinical Trials team led by Dr. Adam Boxer in which he participates in patient evaluation and monitoring. He provides care to patients with various neurodegenerative disorders and collaborates in the evaluation of patients for the Alzheimer's Disease Research Center (ADRC), frontotemporal dementia program project grant and Rapidly Progressive Dementia Program. Dr. Rojas is interested in experimental neurotherapeutics, and his research focuses on biomarker development and cognitive enhancing interventions.

Emma Hare

Senior Research Coordinator

Emma is a senior research coordinator working on Dr. Boxer’s clinical trials and is the primary study coordinator for a phase I corticobasal syndrome and progressive supranuclear palsy treatment trial.

Noelle Ohanesian

Asst. Clinical Research Coordinator

Originally from upstate New York, Noelle graduated from Duke University in May 2014 with a Bachelor of Science degree in neuroscience and a history minor. While attending school, she worked as a research assistant in Duke's Center for Cognitive Neuroscience, running a study examining the effects of acute stress on memory retention. She also spent a summer working for the Behavioral Lab in the Duke University Fuqua School of Business studying social mimicry in anorexic subjects. Outside of her academic interests, she worked as the Program Director of Duke’s backpacking organization, Project WILD, in which she directed one- and two-week backpacking programs for the freshmen class. Noelle joined the UCSF Memory and Aging Center in June 2014 as a member of the clinical trials team under Dr. Adam Boxer. She is a research coordinator for the asymptomatic Alzheimer’s disease trial.

Caitlin Glennon

Analyst

Caitlin joined the Memory and Aging Center in March 2014. She is currently an analyst working on Dr. Boxer’s clinical trials and research studies. She previously worked in the Department of Neurology at UCSF with the Stroke Sciences Group on both industry and NIH-funded clinical trials.

Asymptomatic Alzheimer’s Disease Anti-Amyloid Trial

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (the protein that forms plaques in the brains of people with Alzheimer’s disease) as compared with placebo in subjects with preclinical AD.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Eli Lilly & Company and National Institute on Aging (NIA)
  • Recruiting?: Yes
  • Official study title: Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
  • ClinicalTrials.gov identifier: NCT02008357

Daniel Schonhaut

Research Coordinator

Daniel Schonhaut is a research associate with Dr. Rabinovici and works on amyloid imaging projects.

Emmeline Chuu

Research Coordinator

Emmeline received a bachelor's degree in biology from Reed College in Portland, Oregon, where she completed her thesis on molecular cell biology, focusing on estrogen-mediated regulation of gene expression. Emmeline joined Dr. Adam Boxer’s clinical trials team at the UCSF Memory and Aging Center in December 2013.

Publications

A selection of the abstracts and manuscripts published using EXAMINER data.

The publications listed on this page are a selection of the articles published that used the EXAMINER battery. If you wish to look for more, you can search PubMED, which is maintained by the National Library of Medicine, or Google Scholar.

Manuscripts

  1. Kramer, J.H. (2014). Special Series Introduction: NIH EXAMINER and the Assessment of Executive Functioning. Journal of the International Psychological Society, 20(1), 8-10. doi: 10.1017/S1355617713001185

Panos Theofilas, PhD

Postdoctoral Scholar

Panos Theofilas joined the Grinberg lab at the UCSF Memory and Aging Center in 2012. His research focuses on the neuropathological changes and susceptibility of subcortical brain regions in the earliest stages of Alzheimer's disease. Dr. Theofilas’ methodology includes analyses of human brain circuitries as a whole by combining unbiased stereology, immunohistochemistry/biochemical assays, and 3D computer graphics for histological brain volume reconstructions. His academic background includes a BSc degree in zoology and an MSc degree in neuroscience from the University of Edinburgh, UK. He completed his PhD degree at Bonn University in Germany on programmed cell death signaling pathways in animal models of temporal lobe epilepsy.

Alzheimer’s Disease Trial of Levetiracetam

The purpose of this study is to evaluate whether the anti-epileptic drug levetiracetam reduces subclinical (clinically silent) epileptiform activity and improves cognition in people with Alzheimer’s disease. Epileptiform activity is a term used to describe the abnormal firing of neurons in ways similar to epilepsy or seizure disorder.

Summary

  • Study director: Keith Vossel, MD, MSc
  • Sponsor: Alzheimer’s Association, Inc.; NIH National Institute on Aging; S.D. Bechtel, Jr. Foundation
  • Recruiting?: Yes
  • Official study title: A Phase 2A Levetiracetam Trial for Alzheimer’s Disease—Associated Network Hyperexcitability
Syndicate content